China Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Chinese Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 33.4%, reaching USD 1.90 billion in 2031 from USD 0.45 billion in 2026.

Key Highlights

Market Overview

Demand is supported primarily by China's expanding diabetic population, increasing diagnosis rates, and government efforts to improve chronic disease management. According to the International Diabetes Federation, China accounts for the world's largest population of adults living with diabetes, creating sustained demand for diagnostic monitoring technologies across both urban and developing healthcare systems. Hospitals remain the largest institutional buyers because insulin-dependent patients, critically ill patients, and individuals with poorly controlled diabetes require continuous monitoring to support clinical decision-making. Outside hospital settings, growing patient awareness and wider availability of wearable medical technologies are encouraging greater adoption within home care.

Commercial competition increasingly extends beyond sensor accuracy alone. Purchasing decisions now incorporate sensor wear duration, calibration requirements, mobile application compatibility, interoperability with insulin delivery systems, after-sales technical support, regulatory approval status, and overall cost of ownership. Domestic manufacturers are strengthening their competitive position through locally developed products that address pricing sensitivity and regulatory requirements, while multinational companies continue to differentiate through established clinical evidence, extensive physician education, integrated software platforms, and broad product portfolios.

The market also reflects China's broader healthcare modernization agenda. Digital hospital construction, expansion of internet healthcare services, and increasing use of connected medical devices are encouraging healthcare providers to integrate continuous patient monitoring into routine diabetes care. These structural changes are expanding commercial opportunities for device manufacturers, software providers, distributors, and service partners while raising expectations for data security, product reliability, and clinical validation.

Key Market Indicators

Key indicator: China has approximately 148 million adults living with diabetes, according to the International Diabetes Federation.

Commercial meaning: The size of the diabetic population creates sustained replacement demand for glucose monitoring devices, sensors, consumables, and digital disease management services.

Market Drivers

Expanding diabetes burden is increasing long-term monitoring requirements.

China continues to report the world's largest diabetic population, increasing demand for technologies that improve glycemic control and reduce complications associated with poorly managed diabetes. Clinical guidelines increasingly recommend continuous glucose monitoring for insulin-treated patients because continuous data supports treatment optimization better than intermittent testing. Healthcare providers are therefore incorporating CGM into routine diabetes management for selected patient groups, while manufacturers continue expanding physician education, clinical evidence generation, and product availability to capture rising demand from both hospital and outpatient settings.

Healthcare reforms are strengthening chronic disease management across the care pathway.

Government healthcare reforms increasingly emphasize prevention, standardized diabetes management, and improved long-term treatment outcomes. National initiatives supporting digital healthcare infrastructure, hospital modernization, and hierarchical medical services have encouraged broader adoption of connected diagnostic technologies. Hospitals are investing in systems that improve patient monitoring while reducing preventable diabetes-related complications and hospital readmissions. These policy priorities also encourage manufacturers to pursue local production, regulatory approvals, and partnerships with healthcare institutions that support broader commercialization throughout China's healthcare network.

Growing acceptance of wearable digital health technologies is expanding home-care adoption.

Patients managing diabetes increasingly prefer monitoring solutions that reduce repeated finger-prick testing while providing continuous glucose visibility through smartphone applications and cloud-connected platforms. Home-based monitoring has become more practical as sensors offer longer wear periods, improved accuracy, and easier insertion procedures. Manufacturers are responding by integrating mobile applications, remote data sharing, clinician dashboards, and compatibility with insulin management systems. These capabilities support physician oversight outside hospitals and strengthen recurring revenue opportunities through repeat sensor purchases and digital health services.

Domestic medical device innovation is increasing product availability and market competition.

China's medical device industry continues to receive policy support encouraging domestic innovation, manufacturing investment, and technological self-sufficiency. Local CGM manufacturers are expanding research, obtaining regulatory approvals, and improving sensor performance while offering products that address cost-sensitive customer segments. Competition from domestic suppliers is encouraging multinational companies to strengthen localization strategies, expand distribution networks, invest in physician training, and introduce updated product generations. Greater supplier diversity is improving product accessibility across hospitals, clinics, and home-care channels while encouraging continuous product improvement across the industry.

Market Restraints and Challenges

Limited reimbursement continues to influence purchasing decisions.

Despite the expansion of China's public healthcare system, reimbursement for continuous glucose monitoring (CGM) remains inconsistent across provinces and healthcare programs. Many patients continue to bear a substantial share of sensor and transmitter costs, particularly for long-term home monitoring. Hospitals generally prioritize CGM for insulin-dependent, high-risk, or critically ill patients where clinical benefits are well established, while broader patient adoption often depends on personal affordability. Suppliers are responding through localized manufacturing, tiered product portfolios, and partnerships with healthcare institutions to improve accessibility without compromising product performance.

Regulatory approval and clinical validation increase commercialization timelines.

Medical devices marketed in China must comply with regulatory requirements established by the National Medical Products Administration (NMPA), including product testing, clinical evaluation where required, quality management compliance, and post-market surveillance obligations. These processes extend development schedules and increase commercialization costs, particularly for companies introducing new sensor technologies or software-based monitoring functions. Domestic manufacturers with established regulatory experience may reach commercialization more efficiently, while international suppliers often strengthen local regulatory teams and collaborate with Chinese clinical institutions to support product approvals.

Sensor performance expectations continue to raise research and manufacturing costs.

Healthcare providers increasingly evaluate CGM systems using measures such as accuracy, sensor wear duration, calibration needs, reliability during daily activities, connectivity, and interoperability with insulin delivery platforms. Meeting these expectations requires continued investment in sensor chemistry, miniaturization, software algorithms, cybersecurity, and manufacturing quality control. Product recalls or inconsistent sensor performance can affect physician confidence and purchasing decisions. Consequently, manufacturers continue allocating resources to clinical validation, quality assurance, and product improvements to maintain competitiveness in both hospital and home-care markets.

Price competition is intensifying as domestic manufacturers expand.

China's expanding domestic CGM industry has introduced additional competition across hospital procurement and retail distribution channels. Local suppliers increasingly offer products designed to meet the clinical requirements of cost-sensitive healthcare providers while competing aggressively on price. Multinational manufacturers continue differentiating through extensive clinical evidence, established physician relationships, integrated digital ecosystems, and broader international product portfolios rather than competing solely on device cost. This competitive environment is increasing pricing pressure while encouraging product differentiation through software, patient support services, and data management capabilities.

Major Segment Analysis

Diabetes Patients

Diabetes patients represent the most commercially important application segment because continuous glucose monitoring directly supports long-term glycemic management, insulin dose adjustment, and prevention of acute and chronic diabetes-related complications. Clinical practice increasingly recognizes the value of continuous glucose data in improving treatment decisions for individuals with Type 1 diabetes, insulin-treated Type 2 diabetes, gestational diabetes requiring intensive monitoring, and selected high-risk patient groups. As diagnosis rates increase across China, healthcare providers are incorporating CGM into individualized treatment plans for patients requiring closer metabolic control.

Purchasing priorities differ between institutional buyers and individual users. Hospitals generally emphasize clinical accuracy, interoperability with hospital information systems, reliability, and regulatory compliance, whereas home users place greater weight on affordability, comfort, smartphone connectivity, sensor wear duration, and ease of application. Suppliers therefore compete by balancing clinical performance with user experience while expanding digital services that allow physicians to review glucose trends remotely. Although critical care applications remain an important use case within hospitals, diabetes management generates recurring demand through repeat sensor replacement, software services, and long-term patient monitoring, making it the primary commercial opportunity across the broader market.

Competitive Landscape

Competition in China's continuous glucose monitoring (CGM) market combines established multinational manufacturers with an expanding group of domestic medical device companies. Abbott Laboratories, Dexcom, Inc., Medtronic plc, Roche Diabetes Care, Inc., Ypsomed AG, Senseonics Holdings, Inc., Insulet Corporation, and Tandem Diabetes Care, Inc. compete primarily through clinical evidence, sensor accuracy, software capabilities, physician engagement, and integration with broader diabetes management ecosystems. Their strategies increasingly emphasize localized commercialization, regulatory compliance, and partnerships with healthcare providers to strengthen market access.

Domestic manufacturers, including Zhejiang POCTech Medical Technology Co., Ltd. and Biolight Meditech Co., Ltd., are expanding product portfolios and manufacturing capabilities while targeting price-sensitive customer segments and wider regional distribution. Competition is extending beyond hardware performance to include digital platforms, remote patient monitoring, cloud-based data management, customer support, and after-sales service. Higher regulatory standards, continuous investment in research and development, and the need for strong clinical validation continue to create meaningful entry barriers, particularly for companies introducing new sensor technologies or integrated digital health solutions.

Recent Developments

• March 2026: Shanghai Uniying Microelectronics received China NMPA approval for its uCGM 100 CGM system, marking entry into domestic CGM market with calibration-free sensors designed for hospital-grade accuracy and chronic diabetes monitoring.

• January 2026: Tangjian Medical submitted its Instara-1 CGM for NMPA Registration in China. The breakthrough 21-day, high-precision wearable aims to shift the competitive landscape from price to endurance.

• November 2025: MicroTech Medical secured overseas regulatory approval for its LinX CGM system, supporting international expansion of Chinese-developed real-time glucose monitoring technology and strengthening competitive positioning in Asia-Pacific diabetes care markets.

• March 2025: China's National Medical Products Administration approved an affordable CGM Sensor developed by a local startup. The 14-day wearable aims to expand diabetes monitoring access in rural Chinese markets.

Regulatory and Policy Environment

China's regulatory framework for continuous glucose monitoring devices is primarily administered by the National Medical Products Administration (NMPA), which oversees product registration, quality management, manufacturing standards, clinical evaluation, and post-market surveillance. Manufacturers must demonstrate product safety, effectiveness, and compliance before commercialization. Software functions supporting glucose monitoring are also subject to medical device regulatory requirements when they perform clinical functions, increasing the importance of cybersecurity, software validation, and lifecycle quality management.

Government healthcare policies continue to support broader chronic disease management under the Healthy China initiative while encouraging domestic medical technology innovation and manufacturing capability. National procurement reforms, healthcare digitalization, and expansion of internet healthcare services are improving the environment for connected medical devices, although reimbursement policies for CGM remain more variable than for conventional glucose monitoring products. Companies seeking sustainable growth increasingly align product development with domestic manufacturing policies, regulatory expectations, and evolving hospital procurement requirements.

Outlook and Strategic Implications

Demand for continuous glucose monitoring in China is expected to remain supported by structural healthcare trends rather than short-term purchasing cycles. The country's growing diabetic population, expanding elderly demographic, and increasing focus on long-term disease management continue to strengthen demand for technologies that improve glucose control while reducing diabetes-related complications. Hospitals are expected to remain an important source of institutional demand, while home-based monitoring is likely to account for a larger share of new device adoption as patients become more familiar with wearable monitoring technologies.

Commercial success will increasingly depend on product differentiation beyond sensor performance. Buyers are evaluating complete diabetes management ecosystems that combine accurate sensing, intuitive software, remote physician access, cybersecurity, technical support, and compatibility with insulin delivery devices. Domestic manufacturers are expected to improve their competitive position through localized production, cost optimization, and faster adaptation to Chinese healthcare requirements, while multinational suppliers are likely to emphasize clinical evidence, physician education, premium product positioning, and integrated digital health capabilities.

Strategic priorities across the forecast period include:

• Manufacturers: Expand local manufacturing, strengthen clinical evidence, and improve software integration while maintaining regulatory compliance.

• Hospitals and healthcare providers: Prioritize interoperable CGM platforms that improve clinical workflow, patient monitoring, and long-term diabetes management.

• Technology providers: Develop secure cloud platforms, artificial intelligence-assisted analytics, and remote monitoring capabilities that support physician decision-making.

• Investors: Focus on companies demonstrating sustained regulatory approvals, product differentiation, manufacturing scale, and recurring sensor revenue.

• Policymakers: Continue improving chronic disease management programs, digital healthcare infrastructure, and reimbursement mechanisms to expand patient access to clinically validated monitoring technologies.

Over the 2026-2031 forecast period, competitive advantage is expected to depend less on hardware specifications alone and more on each supplier's ability to deliver integrated diabetes management solutions supported by regulatory compliance, digital connectivity, localized manufacturing, and long-term clinical value.

China Continuous Glucose Monitoring Market Scope: